Sort
51,593 grants matching “hepatitis”
Molecular Approaches To Antiviral and Vaccine Development For Viral Hepatitis
$997,377T. Jake Liang · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2019 · DK
Reperfusion Injury Protection Strategies During Basic Life Support
$997,084Demetris Yannopoulos · University Of Minnesota · R01 · FY2015 · HL
Development of Hepatitis C Virus Inhibitors
$996,920Progenics Pharmaceuticals, Inc. · R44 · FY2005 · AI
Rapid point-of-care molecular test for HCV VL
$996,914Jay Kenneth Fisher · Redbud Labs, Inc. · R44 · FY2025 · AI
Developmental Core
$996,889Herman F. Staats · Duke University · P30 · FY2023 · AI
THE SOUTHEASTERN COOPERATIVE HEPATITIS C RESEARCH GROUP
$996,802University Of Texas Medical Br Galveston · U19 · FY2002 · AI
The PIP2-virus interface and PI 4-kinase: novel biology and validation targets
$996,649Jeffrey S Glenn · Stanford University · R01 · FY2016 · AI
The Florida Node Alliance of the National Drug Abuse Treatment Clinical Trials Network
$996,450Jose Szapocznik · University Of Miami School Of Medicine · UG1 · FY2017 · DA
Individual, Network and Spatial Drivers of HIV and HCV among PWID in India
$996,173Sunil Suhas Solomon · Johns Hopkins University · R01 · FY2020 · DA
Subclinical Vascular Disease and Metabolic Abnormalities in MACS
$996,118Wendy S Post · Johns Hopkins University · R01 · FY2011 · HL
Point-of-Care Rapid RNA test for HIV
$995,819Hyundae Cho · Crosslife Technologies, Inc. · R44 · FY2019 · AI
Development of an oxygen delivery biotherapeutic for the preservation of myocardial function during pediatric cardiopulmonary bypass
$995,592Jonathan A Winger · Omniox, Inc. · R44 · FY2024 · HD
Naloxone Nasal Spray Development
$995,554Daniel Paul Wermeling · Antiop, Inc. · R42 · FY2014 · DA
An Interdisciplinary Approach to HIV and Other Infectious Diseases of Drug Users
$995,241Sherry Deren · New York University · P30 · FY2010 · DA
Advancing a novel potent double anti-HCV nucleoside analog combination treatment for the OUD population to the clinic
$995,102Klaus Klumpp · Riboscience, Llc · R44 · FY2019 · DA
Advancing a novel potent double anti-HCV nucleoside analog combination treatment for the OUD population to the clinic
$995,102Klaus Klumpp · Riboscience, Llc · R44 · FY2020 · DA
Advancing a novel potent double anti-HCV nucleoside analog combination treatment for the OUD population to the clinic
$995,102Klaus Klumpp · Riboscience, Llc · R44 · FY2021 · DA
Advancing a novel potent Zika virus specific nucleoside analog to the clinic
$995,099Klaus Klumpp · Riboscience, Llc · R44 · FY2019 · AI
2/2 Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE Trial)
$994,923Maria Mori Brooks · University Of Pittsburgh At Pittsburgh · U24 · FY2019 · HL
Understanding, Predicting and Preventing Type 2 Diabetes in Youth, Boston Clinical Center (UPP Study)
$994,789Elvira Marie Isganaitis · Joslin Diabetes Center · U01 · FY2025 · DK
Comparative Genomics: Mechanism(s) Against Emerging Infectious Diseases
$994,571Stephen J O'Brien · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA
Human Polycystic Kidney Disease
$994,516University Of Colorado Denver · P01 · FY2003 · DK
Washington Entrepreneurial Research Evaluation and Commercialization Hub
$994,469Rodney J.y. Ho · University Of Washington · U01 · FY2021 · HL
Washington Entrepreneurial Research Evaluation and Commercialization Hub
$994,469Rodney J.y. Ho · University Of Washington · U01 · FY2022 · HL
Washington Entrepreneurial Research Evaluation and Commercialization Hub
$994,469Rodney J.y. Ho · University Of Washington · U01 · FY2020 · HL